In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Baricitinib.Shots:If approved, Baricitinib could be the first JAK inhibitor…
Digital healthcare means using communications and information technologies in medicine to diagnose, predict, treat, and monitor diseases. It is also widely used for prognosis, rehabilitation, behavioral health, and public health.…
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded…
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop itLife sciences companies are putting all of their efforts…
With the race to develop an effective vaccine becoming intense, how has the coronavirus pandemic changed the pharmaceutical industry, and what can we expect in the long- and short-term? Let's…
To remain successful in the oncology market- change is now a key to adapt to this altering market dynamics. A recent development in science and technology platforms are likely to…
In a recent interview with PharmaShots, Dr. Neil Collinson, the Senior Principal Clinical Development Scientist at Genentech / Roche shares his insights and highlights on Xofluza.Shots:The P-III BLOCKSTONE…
The US FDA has approved multiple NDAs and BLAs in Aug 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and…
In late 2019, a mysterious virus causing infection consisting of dry cough, fever tiredness, and last pneumonia first appeared in Wuhan, China. The world health organization (WHO) named the disease…
The US FDA has accepted the sBLA for a new self-administration option for Xolair (omalizumab) across all approved US indications.In an interview with PharmaShots, Ted Omachi the Global Development…